Gilead Sciences, Inc. (NASDAQ:GILD) – Equities researchers at Leerink Swann decreased their Q3 2017 EPS estimates for shares of Gilead Sciences in a research report issued to clients and investors on Monday. Leerink Swann analyst G. Porges now anticipates that the biopharmaceutical company will earn $2.01 per share for the quarter, down from their prior estimate of $2.32. Leerink Swann has a “Market Perform” rating and a $89.00 price objective on the stock. Leerink Swann also issued estimates for Gilead Sciences’ Q4 2017 earnings at $1.73 EPS, FY2017 earnings at $8.44 EPS, FY2018 earnings at $7.20 EPS, FY2019 earnings at $7.10 EPS, FY2020 earnings at $7.48 EPS and FY2021 earnings at $7.90 EPS.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the prior year, the company posted $3.08 earnings per share. Gilead Sciences’s revenue for the quarter was down 8.2% compared to the same quarter last year.
ILLEGAL ACTIVITY WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/10/18/gilead-sciences-inc-to-post-q3-2017-earnings-of-2-01-per-share-leerink-swann-forecasts-gild.html.
Other research analysts have also recently issued research reports about the stock. Jefferies Group LLC reiterated a “hold” rating and set a $80.00 price target on shares of Gilead Sciences in a report on Tuesday, July 11th. BMO Capital Markets reiterated an “outperform” rating and set a $82.00 price target (up previously from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Robert W. Baird reiterated an “outperform” rating and set a $87.00 price target on shares of Gilead Sciences in a report on Thursday, July 13th. J P Morgan Chase & Co reiterated an “overweight” rating and set a $82.00 price target on shares of Gilead Sciences in a report on Tuesday, July 4th. Finally, BidaskClub upgraded shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Twelve research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $85.80.
Shares of Gilead Sciences (GILD) opened at 80.24 on Wednesday. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $86.27. The stock has a market cap of $104.79 billion, a PE ratio of 8.72 and a beta of 1.14. The company’s 50-day moving average is $82.48 and its 200-day moving average is $72.25.
The business also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were paid a $0.52 dividend. The ex-dividend date was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.59%. Gilead Sciences’s dividend payout ratio is currently 22.58%.
In related news, EVP Gregg H. Alton sold 40,000 shares of Gilead Sciences stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $74.00, for a total value of $2,960,000.00. Following the transaction, the executive vice president now owns 137,488 shares of the company’s stock, valued at approximately $10,174,112. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total value of $5,563,041.38. Following the completion of the transaction, the insider now directly owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. Insiders sold a total of 486,819 shares of company stock worth $39,298,919 in the last three months. 1.30% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in Gilead Sciences by 1.9% during the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after acquiring an additional 1,937,031 shares in the last quarter. Vanguard Group Inc. grew its stake in Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after acquiring an additional 2,148,697 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Gilead Sciences by 1.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock valued at $2,185,784,000 after acquiring an additional 310,607 shares in the last quarter. FMR LLC grew its stake in Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after acquiring an additional 258,005 shares in the last quarter. Finally, Parnassus Investments CA grew its stake in Gilead Sciences by 37.4% during the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after acquiring an additional 4,556,901 shares in the last quarter. 73.97% of the stock is currently owned by institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.